<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="224571">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159003</url>
  </required_header>
  <id_info>
    <org_study_id>132910-HMO-CTIL</org_study_id>
    <nct_id>NCT00159003</nct_id>
  </id_info>
  <brief_title>Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel</brief_title>
  <official_title>Molecular Analysis of Genetic Elements Which May Influence Predisposition and Prognosis of Hematological Malignancies in Different Ethnic Groups in Israel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are naturally occuring variations in the genetic makeup of all of us. Some of these
      variations may contribute to a change in susceptibility toward different diseases or change
      the prognosis.

      We are studying these genetic variations in patients with leukemia. The genes we are
      studying are those which influence detoxification of drugs and toxins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have prepared DNA on patients with leukemia (AML, CML and CLL) and we are studying the
      influence of polymorphisms in drug metabolism and disposition genes on predisposition and
      prognosis of these types of leukemia. The genes we are studying include: MDR1, CYP3A4, NQO1,
      NAT1/2, GST, hOCT. We plan to study other genes that may be contributory.

      Study includes comparing the frequency of polymorphisms in these genes with the frequency in
      the general population and the study of DNA biding proteins which bind at the sites of these
      polymorphisms.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 1998</start_date>
  <completion_date type="Anticipated">April 2012</completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA only
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to Hadassah Hospital with AML or CLL.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of acute myeloid leukemia or chronic lymphocytic leukemia

        Exclusion Criteria:

          -  under 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah G Rund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah G Rund, MD</last_name>
    <phone>972-2-6778712</phone>
    <email>rund@cc.huji.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>IL91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah G Rund, MD</last_name>
      <phone>972-2-6778712</phone>
      <email>rund@cc.huji.ac.il</email>
    </contact>
    <investigator>
      <last_name>Deborah G Rund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Chanock S. Genetic variation and hematology: single-nucleotide polymorphisms, haplotypes, and complex disease. Semin Hematol. 2003 Oct;40(4):321-8. Review.</citation>
    <PMID>14582082</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 22, 2011</lastchanged_date>
  <firstreceived_date>September 8, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Deborah Rund</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <keyword>drug metabolism and disposition enzymes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
